Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal model (rat) experiment
PubMed 34547895 · doi:10.1021/acsbiomaterials.1c00792
What was done
Cysteamine-grafted γ-polyglutamic acid (SH-PGA) was synthesized by conjugating cysteamine to the carboxyl groups of γ-PGA, yielding a thiol grafting amount of 4.5 ± 0.3 mmol/g. A 4% polymer hydrogel loaded with the tripeptide KPV (Lys-Pro-Val) was created via thiol self-cross-linking without external chemical cross-linkers. The formulation was characterized for rheological properties, shear-thinning, in vitro release profile, and stability at 37 °C. In vivo therapeutic efficacy was evaluated following rectal administration in a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced ulcerative colitis rat model, measuring body weight, disease activity index, colon length, myeloperoxidase activity, histological structure, and inflammatory cytokines (TNF-α, IL-6).
What was found
The hydrogel exhibited higher elastic modulus (G') than viscous modulus (G'') from 0.01 to 10 Hz and demonstrated shear-thinning behavior. In vitro release showed 30% of KPV released within 20 min followed by sustained release, retaining functional stability after 2 h at 37 °C. In TNBS-treated rats, rectally administered KPV/SH-PGA attenuated weight loss and disease activity scores, prevented colon shortening, reduced colonic myeloperoxidase levels, decreased TNF-α and IL-6 expression, and improved histological recovery of the epithelial barrier, crypts, and goblet cells. Exact quantitative values and variance for in vivo outcomes were not reported in the abstract.
Why it matters
Rectal delivery of therapeutic peptides like KPV is typically hindered by rapid degradation and poor retention. This self-cross-linked hydrogel offers a potential carrier system that stabilizes the peptide and provides localized, sustained release to treat colonic inflammation.
Limits
The study is limited to in vitro testing and an acute chemical rat model of colitis, which does not replicate the chronic, complex pathophysiology of human ulcerative colitis. The abstract omits sample sizes, numeric values, and statistical comparisons for animal outcomes, and long-term toxicity and comparison to standard clinical therapies were not evaluated.
Cited by
- supports The peptide KPV reduces interleukin-6 and TNF-alpha in the gut, which are inflammatory cytokines driving gut inflammation and permeability.